Sana narrows focus again to zero in on diabetes and autoimmune disease
Sana Biotechnology is pruning its pipeline and headcount for the second time in around a year to stretch its cash and support key data readouts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
